SlideShare ist ein Scribd-Unternehmen logo
1 von 70
Diabetes Mellitus Dr. CAI Mengyin Department of Endocrinology 3 rd  Affiliated Hospital Sun Yat-sen University
[object Object],[object Object],[object Object],The official mascots  of the Beijing 2008 Olympic Games Populous country with obesity pandemic Asia countries are facing challenge from Diabetes
Economy taking-off like a rocket  with dramatic lifestyle change State “on Bicycle” Traffic jam in Beijing Coupon for food in Guangzhou One week’s food for a family in Beijing Exercise less Eat More
Prevalence rate of Diabetes Throughout the world: 150 millions ? 2% USA: 15 millions China:  9.7 % --  N Engl J Med 2010;362:1090-101. China: 1980 0.609% in 304537 Canton: 1980 0.411% in 42788
What is Diabetes Mellitus? Definition: Syndrome Metabolic disorder of multiple etiology (causes) characterized by hyperglycemia with carbohydrates, fat, and protein metabolic alterations, which result in defects in the secretion  or action of insulin, or both.
Hyperglycemia X or Metabolic Syndrome Metabolic abnormalities and by long-term  complications involving  eyes, kidneys, nerves, and blood vessels   Acute complications: diabetic ketoacidosis, hyperosmolar nonketotic diabetic coma. homogenous Heterogeneous
Genetic factors Environmental factors Chinese  population  9% Monogenic Polygenic Aging Lifestyle Infections Diabetes Type I <10% Type II >90% Etiology and Development
Defect of β Cell in Insulin Secretion & Action
Non - diabetes Pre - diabetes Diabetes IGT/IFG Fasting plasma  glucose Insulin  requirement Insulin  production <6.1mmol/L >7.0 mmol/L
Derangements are due to relative or absolute insulin deficiency and glucagon excessiveness. Normally, it is a rise in the molar ratio of glucagon to insulin which leads to diabetic decompensation .  Why does metabolic derangement  happen?
 
Spectrum of Diabetes Mellitus Insulin receptor gene mutations (<1%) Insulin gene mutations (<1%) Mitochondrial gene mutations (2%) Type 2 (70%) Type 1 (10%) LADA (10-12% ?) MODY (2-4% ?)
1  yr 10  yr 21  yr 32  yr 45  yr 60  yr Age at diagnosis TYPE1 TYPE2 MODY LADA MIDD DIDMOAD ? Variable Faces of Diabetes Mellitus
Type 1 diabetes mellitus Usually onset before age of 40.  In USA, peak incidence is around 14 years old.  Onset of symptoms may be abrupt, with thirst, excessive urination, increased appetite and weight loss developing over a several-day period. In some cases, the disease is heralded by the appearance of DKA during and intercurrent illness or following surgery.
Type 2 Diabetes Mellitus Usually  starts in middle age or older.  Symptoms begin more gradually than in type 1 diabetes, and diagnosis is frequently made when an asymptomatic person is found to have an elevated plasma glucose on routine lab. Exam..
Type 1 vs. Type 2 Type 1 Type 2 Age of onset Childhood, young adult Adulthood, elder people Body cells Responsive to insulin Resistant to insulin Autoantibodies Positive Negative Body fatness Low to average High Endogenous insulin Little or none Normal or too much Pancreatic function Beta cells not functional Beta cell normal Severity of symptoms Severe; liable to DKA Mild; few or none,  not liable to DKA Insulin shots? Yes, indispensable Not during early and middle stage Drugs? Not solely Yes
 
Maturity-onset diabetes of the young (MODY) 45 33 22 12 16 17 10 INS OHA OHA DIET DIET DIET INS Classical MODY-criteria: 1.  Two patients diagnosed    with diabetes before the    age 25 years. 2.  Autosomal dominant    inheritance of diabetes   (   3 generations) Note: Yellow figures indicating ages at on-set.
History of MODY genes MODY2 GCK MODY1 Linkage to chr20 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 MODY2 Linkage to chr7 MODY3 Linkage to chr12 MODY3 HNF-1  MODY1 HNF-4  MODY5 HNF-1  MODY4 IPF1
 
Severe insulin resistance syndrome Insulin signaling associated mutation Lypodystrophy syndrome linked mutation Other gene IR gene AKT2 gene BSCL FPLD MAD CaR gene AGPAT2 gene Seipin gene LMNA PPARγ gene  LMNA ZMPSTE24 gene
Type A insulin resistance syndrome ,[object Object],[object Object],[object Object]
Sequencing of IR exon20 Black Arrow : P1174W Green Arrow : P1178P Weng J. Clin Endocrinol (Oxf). 2009 Nov; 71(5):659-65. Epub 2009 Jan 19.
Weng J. Clin Endocrinol (Oxf). 2009 Nov; 71(5):659-65. Epub 2009 Jan 19.
HGPS, RD the  “most”  complicated and lethal type of laminopathies HGPS RD Hum Mol Genet, 2004, 13: 2493-2503. N Engl Med, 2008,358: 552-555.
In some other secondary identifiable condition, a diabetic syndrome can develop ,[object Object],[object Object],[object Object],[object Object],[object Object],Mechanism of Stress of Hyperglycemia ,[object Object],[object Object],[object Object]
Gestational Diabetes Mellitus ◆  Definition: Carbohydrates intolerance of variable severity with  onset or first recognition during pregnancy ◆   Screening: American Diabetic Association(ADA) Recommend screening all pregnant women  at 24-26 wks using 50g oral glucose test with 1 hour blood glucose value of 140mg or more as an indication for standard oral glucose tolerance test.  No stipulations as to the time of last meal.
Clinical manifestation   The manifestations of symptomatic diabetes mellitus vary from patient to patient.  Most often medical help is sought because of symptoms related to hyperglycemia: polyuria, polydipsia, polyphagia.
But, the first event may be an acute metabolic decompensation resulting in diabetic coma. More occasionally, the initial expression can be a degenerative complication such as neuropathy in the absence of symptomatic hyperglycemia.
Classifications of Diabetic Vascular Disease ,[object Object],[object Object]
Increased coagulability Platelet hypersensitivity Increased blood viscosity Impaired microvascular flow Increased microvascular pressure and flow Microvascular sclerosis Limitation of maximum perfusion Failure of autoregulation Raised capillary pressure Tissue damage Hypothesis for Diabetic Microangiopathy
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Background ,[object Object],[object Object],[object Object],[object Object],Preproliferative ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Proliferative ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Advanced diabetic eye disease ,[object Object],[object Object],[object Object],[object Object],Maculopathy Stages of Diabetic Retinopathy
Background Proliferative Diabetic Retinopathy
Diabetic Nephropathy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diabetic Neuropathy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Limited joint mobility Motor damage  Sensory damage  Autonomic damage Microcirculatory disease Macrovascular disease Diabetic neuropathy Diabetes ,[object Object],[object Object],[object Object],Abnormal foot posture Reduced pain and proprioception A-V shunting ,[object Object],[object Object],Increased foot pressures Reduced tissue nutrition Callus formation Ischaemia Ulceration Infection Pathways to Diabetic Foot
Foot ulceration Charcot arthropathy Diabetic Foot
Laboratory Findings ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],-  ±  +  ++  +++  ++++
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],6 8 10 12 14 16 18 20 0 10 20 30 40 50 60 control PATIENT 0.693 K (glucose)=  × 100 t  1/2
Insulin (mU/L) 30  60  90  120  150  180  210  min  T2DM Normal T1DM ,[object Object],[object Object],[object Object],[object Object]
C peptide A chain B chain ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diagnosis of Diabetes Mellitus ,[object Object],[object Object],[object Object],[object Object]
Treatment of Diabetes Mellitus Management Goals ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
LDL-c mmol/L <2.5 2.5-4.4 >4.5 ★ According to UKPDS data . Targets for Diabetic Control Good Moderate Poor FPG mmol/L 4.4-6.1 ≤ 7.0 >7.0 PBS mmol/L 4.4-8.0 ≤ 10.0 >10.0 HbA1c ★ % <6.2 6.2-8.0 >8.0 BMI Kg/m 2 M<25 F<24 M<27 F<26 M ≥ 27 F ≥ 26 T ch mmol/L <4.5 ≥ 4.5 6.0 HDL-c mmol/L >1.1 1.1-0.9 <0.9 TG mmol/L <1.5 <2.2 ≥ 2.2
Major Therapeutic Trials 1 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Major Therapeutic Trials 2 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Diet
Food Pyramid ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Physical Activities ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Exercise Guidelines ※   Monitor BG before and after exercise. ※ Avoid exercise if BG >250 mg/dl, ketones present. ※   Use caution with exercise if BG>300 mg/dl, without ketones. ※   Eat CHO if BG < 100 mg/dl ※   If exercise is planned for just after a meal, consider reducing the short acting insulin that covers that meal. ※   If exercise is planned for 3-4 hours after a meal, consider reducing the long-acting insulin. ※   For unplanned exercise, consider adding carbohydrate. ※   Consume CHO before, during, or after exercise to prevent  hypoglycemia. ※   Always keep CHO foods readily available during exercise.
Oral Hypoglycemic Agents
Sulphonylureas ,[object Object],[object Object],[object Object]
Sulfonylurea Activates Insulin Secretion Small figure shows the site of action.
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Secondary Failure ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Biguanides (Metformin) Mode of action: ◇ reduces hepatic glucose production ◇ decreased intestinal absorption of glucose ◇ increases peripheral utalisation of glucose in muscle & fat tissue ◇ decreased insulin requirements for glucose disposal
Precautions:   ● chronic renal or cardiac failure    ● hepatic impairment   ● elderly   ● excessive alcohol intake Side effects: ◆ gastrointestinal disturbances  ◆ metallic taste ◆ malabsorption of B12 Administer:   with or after meals
Alpha Glucosidase Inhibitor  (Acarbose) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Thiazolidinedione ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Insulin ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Insulin preparations and time of reaching peak and duration
Lipoatrophy due to long term injection of ‘impure’ insulin preparations.
Novopen Inhaled insulin Insulin pump
Oral Agents + Insulin in Type 2 Diabetes ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Rationale:
Diabetic Ketoacidosis Presentation Physical examination Laboratory results Polyuria, polydipsia Nausea, vomiting Diarrhea, abd. Pain Evolution for a few days Stupor or coma in Loss of skin turgor Kussmaul breathing  Acetone odor Cerebral edema PH <7.3, HCO 3  <15 Eq/L Glucose > 250 mg/dl Elevated anion gap High serum ketones High uric acid Normal osmolality
Precipitating Factors of DKA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment of DKA – IV fluid Normal saline 1 liter/hr until not orthostatic hypotensive,  then  NS at 500 ml/hr Electrolytes every 2 hrs initially, then every 4 hours Glucose <250 mg/dl, change to Dextrose with 1:4 regular insulin at 250-500 ml/hr  When anion gap normal, bicarbonate >15 mEq/L, taking PO fluid, give meal and SC insulin
Treatment of DKA – Insulin IV insulin at 5-10 u/hr in adult, 0.1 u/kg/hr in child Check glucose hourly, if no change in 2 hrs double the insulin infusion Glucose <250 mg/dl, slow insulin to 2-4 u/hr Discontinue IV insulin 2-3 hrs after SC insulin dose
Treatment of DKA – Potassium Potassium repletion if initial K is normal or low at 10-40 mEq/hr Check potassium every 2- 4 hrs Replete total body potassium stores over 2- 3 days
Treatment of DKA – Bicarbonate, Phosphorus Bicarbonate replacement if pH less than 6.90 Check phosphorus 12 hrs into treatment. Replace if < 1 mEq/L

Weitere ähnliche Inhalte

Was ist angesagt?

Diagnosis of diabetes mellitus
Diagnosis of diabetes mellitus  Diagnosis of diabetes mellitus
Diagnosis of diabetes mellitus
Dilek Gogas Yavuz
 

Was ist angesagt? (20)

Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes Powerpoint 6
Diabetes  Powerpoint 6Diabetes  Powerpoint 6
Diabetes Powerpoint 6
 
Diabetes
DiabetesDiabetes
Diabetes
 
Diabetes mellitus presentation
Diabetes mellitus presentationDiabetes mellitus presentation
Diabetes mellitus presentation
 
Management of Diabetes.pptx
Management of Diabetes.pptxManagement of Diabetes.pptx
Management of Diabetes.pptx
 
Diabetes diagnosis
Diabetes diagnosis Diabetes diagnosis
Diabetes diagnosis
 
Diabetes mellitus , Risk Factors, Classification, Treatment.
Diabetes mellitus , Risk Factors, Classification, Treatment.Diabetes mellitus , Risk Factors, Classification, Treatment.
Diabetes mellitus , Risk Factors, Classification, Treatment.
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes MODY
Diabetes MODYDiabetes MODY
Diabetes MODY
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Diabetes and its Complication
Diabetes and its ComplicationDiabetes and its Complication
Diabetes and its Complication
 
Diabetes mellitus with complication
Diabetes mellitus with complicationDiabetes mellitus with complication
Diabetes mellitus with complication
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes management
Diabetes managementDiabetes management
Diabetes management
 
Type 1 diabetes mellitus
Type 1 diabetes mellitusType 1 diabetes mellitus
Type 1 diabetes mellitus
 
Acute Complication of DM by Dr Shahjada Selim
Acute Complication of DM by Dr Shahjada SelimAcute Complication of DM by Dr Shahjada Selim
Acute Complication of DM by Dr Shahjada Selim
 
Dibetties milliteus
Dibetties milliteusDibetties milliteus
Dibetties milliteus
 
Complications of diabetes melitus
Complications of diabetes melitusComplications of diabetes melitus
Complications of diabetes melitus
 
All what you have to know about Diabetes Mellitus
All what you have to know about Diabetes MellitusAll what you have to know about Diabetes Mellitus
All what you have to know about Diabetes Mellitus
 
Diagnosis of diabetes mellitus
Diagnosis of diabetes mellitus  Diagnosis of diabetes mellitus
Diagnosis of diabetes mellitus
 

Andere mochten auch

19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosis
internalmed
 
11 heart failure
11 heart failure11 heart failure
11 heart failure
internalmed
 
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
internalmed
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
internalmed
 
23 renal disease
23 renal disease23 renal disease
23 renal disease
internalmed
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
internalmed
 
再障 2010.5.13
再障 2010.5.13再障 2010.5.13
再障 2010.5.13
internalmed
 
4 pleural effusions
4 pleural effusions4 pleural effusions
4 pleural effusions
internalmed
 
Foreign students acute leukemia-zhou
Foreign students acute leukemia-zhouForeign students acute leukemia-zhou
Foreign students acute leukemia-zhou
internalmed
 
20 hepatic enchephalopathy
20 hepatic enchephalopathy20 hepatic enchephalopathy
20 hepatic enchephalopathy
internalmed
 
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeC:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
internalmed
 
4 bronchiectasis
4 bronchiectasis4 bronchiectasis
4 bronchiectasis
internalmed
 
22 acute pancreatitis
22 acute pancreatitis22 acute pancreatitis
22 acute pancreatitis
internalmed
 

Andere mochten auch (20)

19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosis
 
11 heart failure
11 heart failure11 heart failure
11 heart failure
 
10 hypertension
10 hypertension10 hypertension
10 hypertension
 
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
23 renal disease
23 renal disease23 renal disease
23 renal disease
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
Anemia
AnemiaAnemia
Anemia
 
9 asthma
9 asthma9 asthma
9 asthma
 
15 ie
15 ie15 ie
15 ie
 
再障 2010.5.13
再障 2010.5.13再障 2010.5.13
再障 2010.5.13
 
4 pleural effusions
4 pleural effusions4 pleural effusions
4 pleural effusions
 
Foreign students acute leukemia-zhou
Foreign students acute leukemia-zhouForeign students acute leukemia-zhou
Foreign students acute leukemia-zhou
 
20 hepatic enchephalopathy
20 hepatic enchephalopathy20 hepatic enchephalopathy
20 hepatic enchephalopathy
 
1 introduction
1 introduction1 introduction
1 introduction
 
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeC:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
 
4 bronchiectasis
4 bronchiectasis4 bronchiectasis
4 bronchiectasis
 
6 lungcancer
6 lungcancer6 lungcancer
6 lungcancer
 
7 cor pulmonale
7 cor pulmonale7 cor pulmonale
7 cor pulmonale
 
22 acute pancreatitis
22 acute pancreatitis22 acute pancreatitis
22 acute pancreatitis
 

Ähnlich wie C:\documents and settings\administrator\桌面\35 ndiabetes mellitus

Diabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementDiabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental management
MedicineAndFamily
 
Diabetes melitus by dr aftab ahmed
Diabetes melitus by dr aftab ahmedDiabetes melitus by dr aftab ahmed
Diabetes melitus by dr aftab ahmed
aaiman46
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
Khalid
 
Diabetes Mellitus & Its Oral Manifestations
Diabetes Mellitus & Its Oral ManifestationsDiabetes Mellitus & Its Oral Manifestations
Diabetes Mellitus & Its Oral Manifestations
khateeb9
 
Diabetes new final compiled
Diabetes new final compiledDiabetes new final compiled
Diabetes new final compiled
Chandrika Verma
 
Ueda2015 diabetic nephropathy dr.ashraf talaat
Ueda2015 diabetic  nephropathy dr.ashraf talaatUeda2015 diabetic  nephropathy dr.ashraf talaat
Ueda2015 diabetic nephropathy dr.ashraf talaat
ueda2015
 

Ähnlich wie C:\documents and settings\administrator\桌面\35 ndiabetes mellitus (20)

Diabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementDiabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental management
 
DIABETES MELLITUS by dr aftab ahmed
DIABETES  MELLITUS by dr aftab ahmedDIABETES  MELLITUS by dr aftab ahmed
DIABETES MELLITUS by dr aftab ahmed
 
Diabetes melitus by dr aftab ahmed
Diabetes melitus by dr aftab ahmedDiabetes melitus by dr aftab ahmed
Diabetes melitus by dr aftab ahmed
 
diabetes-mellitus3143.pptx
diabetes-mellitus3143.pptxdiabetes-mellitus3143.pptx
diabetes-mellitus3143.pptx
 
Diabetic retinopathy
Diabetic retinopathyDiabetic retinopathy
Diabetic retinopathy
 
Dm 1 1
Dm 1 1Dm 1 1
Dm 1 1
 
Ueda 2016 2-pathophysiology ,classification &amp; diagnosis of diabetes - kha...
Ueda 2016 2-pathophysiology ,classification &amp; diagnosis of diabetes - kha...Ueda 2016 2-pathophysiology ,classification &amp; diagnosis of diabetes - kha...
Ueda 2016 2-pathophysiology ,classification &amp; diagnosis of diabetes - kha...
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Diabetes Mellitus & Its Oral Manifestations
Diabetes Mellitus & Its Oral ManifestationsDiabetes Mellitus & Its Oral Manifestations
Diabetes Mellitus & Its Oral Manifestations
 
Diabetes Mellitus Type 2 - Pathology.pptx
Diabetes Mellitus Type 2 - Pathology.pptxDiabetes Mellitus Type 2 - Pathology.pptx
Diabetes Mellitus Type 2 - Pathology.pptx
 
Diabetes mellitus
Diabetes mellitus Diabetes mellitus
Diabetes mellitus
 
RECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS AND ITS COMPLICATIONS
RECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS AND ITS COMPLICATIONSRECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS AND ITS COMPLICATIONS
RECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS AND ITS COMPLICATIONS
 
Diabetes new final compiled
Diabetes new final compiledDiabetes new final compiled
Diabetes new final compiled
 
Ueda2015 diabetic nephropathy dr.ashraf talaat
Ueda2015 diabetic  nephropathy dr.ashraf talaatUeda2015 diabetic  nephropathy dr.ashraf talaat
Ueda2015 diabetic nephropathy dr.ashraf talaat
 
Surgery in diabetes patients Dr nesar Ahmad
Surgery in diabetes patients   Dr nesar AhmadSurgery in diabetes patients   Dr nesar Ahmad
Surgery in diabetes patients Dr nesar Ahmad
 
Presentation final montanya
Presentation final montanyaPresentation final montanya
Presentation final montanya
 
Pathophysiology of diabetes mellitus
Pathophysiology of diabetes mellitusPathophysiology of diabetes mellitus
Pathophysiology of diabetes mellitus
 
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase MethodDetermination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
 
Biomarkers of diabetic retinopathy
Biomarkers of diabetic retinopathyBiomarkers of diabetic retinopathy
Biomarkers of diabetic retinopathy
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 

Mehr von internalmed

内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
internalmed
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular disease
internalmed
 
21 ulcerative colitis
21 ulcerative colitis21 ulcerative colitis
21 ulcerative colitis
internalmed
 
17 pericardial disease
17 pericardial disease17 pericardial disease
17 pericardial disease
internalmed
 
17 chronic gastritis gao
17 chronic gastritis gao17 chronic gastritis gao
17 chronic gastritis gao
internalmed
 
16 arrhythmias2009
16 arrhythmias200916 arrhythmias2009
16 arrhythmias2009
internalmed
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
internalmed
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
internalmed
 
13 respiratory failure
13 respiratory failure13 respiratory failure
13 respiratory failure
internalmed
 

Mehr von internalmed (13)

内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular disease
 
21 ulcerative colitis
21 ulcerative colitis21 ulcerative colitis
21 ulcerative colitis
 
18 peptic ulcer
18 peptic ulcer18 peptic ulcer
18 peptic ulcer
 
17 pericardial disease
17 pericardial disease17 pericardial disease
17 pericardial disease
 
17 chronic gastritis gao
17 chronic gastritis gao17 chronic gastritis gao
17 chronic gastritis gao
 
16 arrhythmias2009
16 arrhythmias200916 arrhythmias2009
16 arrhythmias2009
 
Gastric cancer
Gastric cancerGastric cancer
Gastric cancer
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
 
Gastric cancer
Gastric cancerGastric cancer
Gastric cancer
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
 
Anemia
AnemiaAnemia
Anemia
 
13 respiratory failure
13 respiratory failure13 respiratory failure
13 respiratory failure
 

Kürzlich hochgeladen

The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
heathfieldcps1
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
ciinovamais
 

Kürzlich hochgeladen (20)

INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Role Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptxRole Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptx
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdf
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SD
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 

C:\documents and settings\administrator\桌面\35 ndiabetes mellitus

  • 1. Diabetes Mellitus Dr. CAI Mengyin Department of Endocrinology 3 rd Affiliated Hospital Sun Yat-sen University
  • 2.
  • 3. Economy taking-off like a rocket with dramatic lifestyle change State “on Bicycle” Traffic jam in Beijing Coupon for food in Guangzhou One week’s food for a family in Beijing Exercise less Eat More
  • 4. Prevalence rate of Diabetes Throughout the world: 150 millions ? 2% USA: 15 millions China: 9.7 % -- N Engl J Med 2010;362:1090-101. China: 1980 0.609% in 304537 Canton: 1980 0.411% in 42788
  • 5. What is Diabetes Mellitus? Definition: Syndrome Metabolic disorder of multiple etiology (causes) characterized by hyperglycemia with carbohydrates, fat, and protein metabolic alterations, which result in defects in the secretion or action of insulin, or both.
  • 6. Hyperglycemia X or Metabolic Syndrome Metabolic abnormalities and by long-term complications involving eyes, kidneys, nerves, and blood vessels Acute complications: diabetic ketoacidosis, hyperosmolar nonketotic diabetic coma. homogenous Heterogeneous
  • 7. Genetic factors Environmental factors Chinese population  9% Monogenic Polygenic Aging Lifestyle Infections Diabetes Type I <10% Type II >90% Etiology and Development
  • 8. Defect of β Cell in Insulin Secretion & Action
  • 9. Non - diabetes Pre - diabetes Diabetes IGT/IFG Fasting plasma glucose Insulin requirement Insulin production <6.1mmol/L >7.0 mmol/L
  • 10. Derangements are due to relative or absolute insulin deficiency and glucagon excessiveness. Normally, it is a rise in the molar ratio of glucagon to insulin which leads to diabetic decompensation . Why does metabolic derangement happen?
  • 11.  
  • 12. Spectrum of Diabetes Mellitus Insulin receptor gene mutations (<1%) Insulin gene mutations (<1%) Mitochondrial gene mutations (2%) Type 2 (70%) Type 1 (10%) LADA (10-12% ?) MODY (2-4% ?)
  • 13. 1 yr 10 yr 21 yr 32 yr 45 yr 60 yr Age at diagnosis TYPE1 TYPE2 MODY LADA MIDD DIDMOAD ? Variable Faces of Diabetes Mellitus
  • 14. Type 1 diabetes mellitus Usually onset before age of 40. In USA, peak incidence is around 14 years old. Onset of symptoms may be abrupt, with thirst, excessive urination, increased appetite and weight loss developing over a several-day period. In some cases, the disease is heralded by the appearance of DKA during and intercurrent illness or following surgery.
  • 15. Type 2 Diabetes Mellitus Usually starts in middle age or older. Symptoms begin more gradually than in type 1 diabetes, and diagnosis is frequently made when an asymptomatic person is found to have an elevated plasma glucose on routine lab. Exam..
  • 16. Type 1 vs. Type 2 Type 1 Type 2 Age of onset Childhood, young adult Adulthood, elder people Body cells Responsive to insulin Resistant to insulin Autoantibodies Positive Negative Body fatness Low to average High Endogenous insulin Little or none Normal or too much Pancreatic function Beta cells not functional Beta cell normal Severity of symptoms Severe; liable to DKA Mild; few or none, not liable to DKA Insulin shots? Yes, indispensable Not during early and middle stage Drugs? Not solely Yes
  • 17.  
  • 18. Maturity-onset diabetes of the young (MODY) 45 33 22 12 16 17 10 INS OHA OHA DIET DIET DIET INS Classical MODY-criteria: 1. Two patients diagnosed with diabetes before the age 25 years. 2. Autosomal dominant inheritance of diabetes (  3 generations) Note: Yellow figures indicating ages at on-set.
  • 19. History of MODY genes MODY2 GCK MODY1 Linkage to chr20 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 MODY2 Linkage to chr7 MODY3 Linkage to chr12 MODY3 HNF-1  MODY1 HNF-4  MODY5 HNF-1  MODY4 IPF1
  • 20.  
  • 21. Severe insulin resistance syndrome Insulin signaling associated mutation Lypodystrophy syndrome linked mutation Other gene IR gene AKT2 gene BSCL FPLD MAD CaR gene AGPAT2 gene Seipin gene LMNA PPARγ gene LMNA ZMPSTE24 gene
  • 22.
  • 23. Sequencing of IR exon20 Black Arrow : P1174W Green Arrow : P1178P Weng J. Clin Endocrinol (Oxf). 2009 Nov; 71(5):659-65. Epub 2009 Jan 19.
  • 24. Weng J. Clin Endocrinol (Oxf). 2009 Nov; 71(5):659-65. Epub 2009 Jan 19.
  • 25. HGPS, RD the “most” complicated and lethal type of laminopathies HGPS RD Hum Mol Genet, 2004, 13: 2493-2503. N Engl Med, 2008,358: 552-555.
  • 26.
  • 27. Gestational Diabetes Mellitus ◆ Definition: Carbohydrates intolerance of variable severity with onset or first recognition during pregnancy ◆ Screening: American Diabetic Association(ADA) Recommend screening all pregnant women at 24-26 wks using 50g oral glucose test with 1 hour blood glucose value of 140mg or more as an indication for standard oral glucose tolerance test. No stipulations as to the time of last meal.
  • 28. Clinical manifestation The manifestations of symptomatic diabetes mellitus vary from patient to patient. Most often medical help is sought because of symptoms related to hyperglycemia: polyuria, polydipsia, polyphagia.
  • 29. But, the first event may be an acute metabolic decompensation resulting in diabetic coma. More occasionally, the initial expression can be a degenerative complication such as neuropathy in the absence of symptomatic hyperglycemia.
  • 30.
  • 31. Increased coagulability Platelet hypersensitivity Increased blood viscosity Impaired microvascular flow Increased microvascular pressure and flow Microvascular sclerosis Limitation of maximum perfusion Failure of autoregulation Raised capillary pressure Tissue damage Hypothesis for Diabetic Microangiopathy
  • 32.
  • 34.
  • 35.
  • 36.
  • 37. Foot ulceration Charcot arthropathy Diabetic Foot
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44. LDL-c mmol/L <2.5 2.5-4.4 >4.5 ★ According to UKPDS data . Targets for Diabetic Control Good Moderate Poor FPG mmol/L 4.4-6.1 ≤ 7.0 >7.0 PBS mmol/L 4.4-8.0 ≤ 10.0 >10.0 HbA1c ★ % <6.2 6.2-8.0 >8.0 BMI Kg/m 2 M<25 F<24 M<27 F<26 M ≥ 27 F ≥ 26 T ch mmol/L <4.5 ≥ 4.5 6.0 HDL-c mmol/L >1.1 1.1-0.9 <0.9 TG mmol/L <1.5 <2.2 ≥ 2.2
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50. Exercise Guidelines ※ Monitor BG before and after exercise. ※ Avoid exercise if BG >250 mg/dl, ketones present. ※ Use caution with exercise if BG>300 mg/dl, without ketones. ※ Eat CHO if BG < 100 mg/dl ※ If exercise is planned for just after a meal, consider reducing the short acting insulin that covers that meal. ※ If exercise is planned for 3-4 hours after a meal, consider reducing the long-acting insulin. ※ For unplanned exercise, consider adding carbohydrate. ※ Consume CHO before, during, or after exercise to prevent hypoglycemia. ※ Always keep CHO foods readily available during exercise.
  • 52.
  • 53. Sulfonylurea Activates Insulin Secretion Small figure shows the site of action.
  • 54.
  • 55.
  • 56. Biguanides (Metformin) Mode of action: ◇ reduces hepatic glucose production ◇ decreased intestinal absorption of glucose ◇ increases peripheral utalisation of glucose in muscle & fat tissue ◇ decreased insulin requirements for glucose disposal
  • 57. Precautions: ● chronic renal or cardiac failure ● hepatic impairment ● elderly ● excessive alcohol intake Side effects: ◆ gastrointestinal disturbances ◆ metallic taste ◆ malabsorption of B12 Administer: with or after meals
  • 58.
  • 59.
  • 60.
  • 61. Insulin preparations and time of reaching peak and duration
  • 62. Lipoatrophy due to long term injection of ‘impure’ insulin preparations.
  • 63. Novopen Inhaled insulin Insulin pump
  • 64.
  • 65. Diabetic Ketoacidosis Presentation Physical examination Laboratory results Polyuria, polydipsia Nausea, vomiting Diarrhea, abd. Pain Evolution for a few days Stupor or coma in Loss of skin turgor Kussmaul breathing Acetone odor Cerebral edema PH <7.3, HCO 3 <15 Eq/L Glucose > 250 mg/dl Elevated anion gap High serum ketones High uric acid Normal osmolality
  • 66.
  • 67. Treatment of DKA – IV fluid Normal saline 1 liter/hr until not orthostatic hypotensive, then NS at 500 ml/hr Electrolytes every 2 hrs initially, then every 4 hours Glucose <250 mg/dl, change to Dextrose with 1:4 regular insulin at 250-500 ml/hr When anion gap normal, bicarbonate >15 mEq/L, taking PO fluid, give meal and SC insulin
  • 68. Treatment of DKA – Insulin IV insulin at 5-10 u/hr in adult, 0.1 u/kg/hr in child Check glucose hourly, if no change in 2 hrs double the insulin infusion Glucose <250 mg/dl, slow insulin to 2-4 u/hr Discontinue IV insulin 2-3 hrs after SC insulin dose
  • 69. Treatment of DKA – Potassium Potassium repletion if initial K is normal or low at 10-40 mEq/hr Check potassium every 2- 4 hrs Replete total body potassium stores over 2- 3 days
  • 70. Treatment of DKA – Bicarbonate, Phosphorus Bicarbonate replacement if pH less than 6.90 Check phosphorus 12 hrs into treatment. Replace if < 1 mEq/L